ライフサイエンスコーパス: gal

1 different oil loadings (100, 333, and 1,000 gal acre(-1)) and mixing regimes (fully, moderately, and

2 e initial oil loading was increased to 1,000 gal acre(-1).

3 ing 1/8 teaspoon (or 8 drops) of bleach to 1 gal of water.

4 Galectin-1 (gal-1), a special lectin with high affinity to beta-gala

5 ted the therapeutic potential of galectin-1 (gal-1), an endogenous lectin that in some autoimmune dis

6 ox assay showed no major toxicity at the 100 gal acre(-1) loading.

7 ion in water-use intensity by 40% (2000-1200 gal/ft; 2.5-1.5 m(3)/m).

8 generators with mostly cooling towers (0.19 gal/kWh) being 63% lower than that of traditional coal,

9 luent samples for the concrete, 5 gal, and 2 gal filters, respectively, had E. coli concentrations of

10 d two scaled-down versions that use a 5 or 2 gal bucket as the casing material.

11 h) of greenhouse gas (GHG) emissions and 224 gal/MWh (80% CI: 185-305 gal/MWh) of freshwater consumpt

12 Galectin-3 (gal-3) is a beta-galactoside-binding lectin expressed in

13 Galectin-3 (gal-3) is expressed in well-differentiated and in undiff

14 Galectin-3 (gal-3), the only antiapoptotic member of the galectin fa

15 ckout (DKO)] that produce the gal-alpha(1,3)-gal and N-glycolylneuraminic acid xenoantigens reduces h

16 Porcine RMEC expressed gal-alpha(1,3)-gal, N-glycolylneuraminic acid, and Dolichos biflorus ag

17 vidin-3-glc, myricetin-3-glc and myricetin-3-gal in 2017 season.

18 Inhibition of Tim-3/gal-9 binding by infusion of a Tim-3-Ig fusion protein o

19 When the Tim-3/gal-9 pathway engagement was augmented using gal-9 trans

20 t to show that although the absence of Tim-3/gal-9 pathway interactions augments systemic GVHD, concu

21 Paradoxically, when Tim-3/gal-9 was inhibited in the absence of donor T-regulatory

22 ) emissions and 224 gal/MWh (80% CI: 185-305 gal/MWh) of freshwater consumption.

23 se of the moderately mixed microcosms at 333 gal acre(-1) and was maintained at moderate levels (EC(5

24 rometric microcosms at an oil loading of 333 gal acre(-1) (0.31 L m(-2)) and BHT concentrations rangi

25 72% of effluent samples for the concrete, 5 gal, and 2 gal filters, respectively, had E. coli concen

26 ional amounts needed to reach a target $2.50/gal biofuel selling price, using cellulosic ethanol prod

27 e generators with mostly cooling ponds (0.52 gal/kWh).

28 with mean Bakken water use/well (2.0 x 10(6) gal/well) about half that in the Eagle Ford, and a third

29 nsity is estimated to be between 1.8 and 2.7 gal/MMBtu and is similar to surface coal mining.

30 thogenic T cells, and its ligand galectin-9 (gal-9) is up-regulated in inflamed tissues.

31 times from 2005-2014, totaling 24.5 x 10(9) gal (93 x 10(9) L) for approximately 10140 wells.

32 ditional wells and related HF of 265 x 10(9) gal and FP of 85 x 10(9) gal.

33 d HF of 265 x 10(9) gal and FP of 85 x 10(9) gal.

34 ing access of up to approximately 33 x 10(9) gal/year (125 x 10(9) L/year) from Lake Sakakawea, expan

35 BM agar medium supplemented with X-gal (ABMX-gal).

36 Since the alpha gal epitope is found on gut enterobacteria, it has been

37 Alpha-gal epitopes were detected by immunoblotting on antiveno

38 Alpha-gal is a potential target of IgE-mediated reactivity to

39 Alpha-gal syndrome (AGS) describes a wide spectrum of hypersen

40 Alpha-gal-containing allergens induced strong basophil activat

41 Alpha-gal-containing glycolipids activate basophils sensitized

42 Alpha-gal-sIgE levels were assessed by ImmunoCAP assay.

43 Alpha-gal-sIgE positivity was associated with total IgE levels

44 1 patients with alpha-gal syndrome, 12 alpha-gal-sensitized subjects, and 18 control subjects.

45 Vaccination against alpha-gal confers sterile protection against malaria in mice,

46 h-titer IgE antibodies for Ara h 2 and alpha-gal, respectively.

47 O86:B7 express alpha-gal and that anti-alpha-gal Abs are associated with protection against malaria t

48 Anti-alpha-gal Abs target Plasmodium sporozoites for complement-med

49 nt mice, which produce protective anti-alpha-gal Abs when colonized by E. coli O86:B7.

50 and allowed for the production of anti-alpha-gal antibodies (Abs) in humans, confers protection again

51 By contrast, an anti-alpha-gal IgM antibody response was shown to protect against m

52 ndrome from subjects with asymptomatic alpha-gal sensitization.

53 mpared with subjects with asymptomatic alpha-gal sensitization.

54 Neither the depletion of autologous alpha-gal-specific IgG Ab nor the addition of alpha-gal-specif

55 allergens (eg, commercially available alpha-gal-carrying proteins and pork kidney extracts) was perf

56 hesizes a carbohydrate antigen called "alpha-gal epitope." The alpha-gal epitope is present in large

57 allergic reactions to the carbohydrate alpha-gal after consumption of mammalian (red) meat products a

58 Their enhanced alpha-gal-specific IgE levels are accompanied by high levels o

59 gut pathobiont E. coli O86:B7 express alpha-gal and that anti-alpha-gal Abs are associated with prot

60 ion of mammalian xenografts expressing alpha-gal epitopes in humans, apes, and Old World monkeys.

61 Antivenoms were screened for alpha-gal epitopes via immunoblot and in comparison with cetux

62 loyees and hunters, the odds ratio for alpha-gal-sIgE positivity was 2.48 compared to the residential

63 basophils sensitized with plasma from alpha-gal allergic subjects in an IgE-dependent manner suggest

64 itopes, galactose-alpha-1,3-galactose (alpha-gal) and Neu5Gc-alpha-2-6-galactose (Neu5Gc) have been s

65 nut and galactose alpha-1,3-galactose (alpha-gal) are characterized by high- or very high-titer IgE a

66 charide galactose-alpha-1,3-galactose (alpha-gal) are common in the southeastern United States.

67 IgG to galactose-alpha-1,3-galactose (alpha-gal) are highly abundant natural antibodies (Ab) in huma

68 ific to galactose-alpha-1,3-galactose (alpha-gal) are responsible for a delayed form of anaphylaxis t

69 hydrate galactose-alpha-1,3-galactose (alpha-gal) is known to induce delayed anaphylaxis against mamm

70 Galactose-alpha-1,3-galactose (alpha-gal) syndrome is characterized by the presence of serum

71 pitope, galactose-alpha-1,3-galactose (alpha-gal).

72 charide galactose-alpha-1,3-galactose (alpha-gal).

73 (IgG) that recognizes the heterophilic alpha-gal epitope.

74 c patients showed significantly higher alpha-gal-specific IgG1 and IgG3 Ab than nonallergic individua

75 prevalence of alpha-gal-specific IgE (alpha-gal-sIgE) positivity varies between different population

76 mans, apes, and Old World monkeys lack alpha-gal epitopes and naturally produce an antibody called th

77 s transplanted with pig organs lacking alpha-gal epitopes have suggested that anti-non gal antibodies

78 ed that the antivenoms contained lower alpha-gal contents than cetuximab.

79 od allergies and distinct from natural alpha-gal IgG responses in nonallergic individuals.

80 explained by the delayed expression of alpha-gal due to digestive processes.

81 Establishing the source of alpha-gal in arthropod vectors and the immune response to vect

82 tick bites which induce production of alpha-gal specific IgE antibodies that lead to (at times fatal

83 The identification of alpha-gal syndrome in patients with IA supports the need for r

84 CAST) with different concentrations of alpha-gal-containing allergens (eg, commercially available alp

85 a population with a high prevalence of alpha-gal-sIgE positivity and carry a considerable risk of red

86 To investigate the prevalence of alpha-gal-sIgE positivity in a population of forest service em

87 The prevalence of alpha-gal-sIgE positivity in the current and historic cohort w

88 he study population, the prevalence of alpha-gal-sIgE-positive (>/=0.10 kUA /L) individuals was 35.0%

89 The prevalence of alpha-gal-sIgE-positive individuals was compared with a matche

90 The reported prevalence of alpha-gal-specific IgE (alpha-gal-sIgE) positivity varies betw

91 al-specific IgG Ab nor the addition of alpha-gal-specific IgG Ab from nonallergic individuals changed

92 vels are accompanied by high levels of alpha-gal-specific IgG1 devoid of IgE-blocking activity.

93 showed significantly higher levels of alpha-gal-specific IgG4 Ab.

94 d the protective or allergic effect of alpha-gal.

95 rate Galalpha1-3Galbeta1-(3)4GlcNAc-R (alpha-gal) following a tick bite was associated with allergies

96 of the Galalpha1-3Galbeta1-4GlcNAc-R (alpha-gal) glycan and allowed for the production of anti-alpha

97 ctions mediated by specific IgE to the alpha-gal epitope (galactose-alpha-1,3-galactose) ubiquitously

98 r serum IgE antibodies directed to the alpha-gal epitope are associated with hypersensitivity to equi

99 ntigen called "alpha-gal epitope." The alpha-gal epitope is present in large numbers on cell membrane

100 IgG Ab that selectively recognize the alpha-gal epitope on BGG.

101 Once the alpha-gal epitope was eliminated, primates could produce the a

102 ests with cetuximab, which carries the alpha-gal epitope.

103 ion of primate populations lacking the alpha-gal epitope.

104 ge of CD63(+) basophils induced by the alpha-gal-containing allergen to the percentage of CD63(+) bas

105 such reactions and characterized their alpha-gal-specific IgE and IgG responses in more detail.

106 several hours in patients with IgE to alpha-gal (galactose-alpha-1,3-galactose) have been reported.

107 tients with specific IgE antibodies to alpha-gal and 10 controls.

108 association between IgE antibodies to alpha-gal and asthma (odds ratios, 1.04 and 0.75, respectively

109 ce of serum specific IgE antibodies to alpha-gal and delayed type I allergic reactions to the carbohy

110 al reactions but lower specific IgE to alpha-gal and higher serum tryptase levels, reflective of the

111 mammalian meat in subjects with IgE to alpha-gal and to monitor ex vivo for the appearance of markers

112 use of anaphylaxis, where reactions to alpha-gal are delayed and thus may be overlooked.

113 antibody" which binds specifically to alpha-gal epitopes and which is the most abundant antibody in

114 Ten of 12 subjects with IgE to alpha-gal had clinical evidence of a reaction during the food

115 inia with high-titer IgE antibodies to alpha-gal had normal lung function, low levels of exhaled nitr

116 IgE to alpha-gal has been associated with 2 distinct forms of anaphyl

117 nt cause, of IgE antibody responses to alpha-gal in the southern, eastern, and central United States;

118 the specific IgE antibody response to alpha-gal will be an important aspect to address as this area

119 ed basophils from patients with IgE to alpha-gal.

120 A), six (9%) were found to have IgE to alpha-gal.

121 test results in patients with sIgE to alpha-gal.

122 ensitization source, as ticks transfer alpha-gal in their saliva to a host during a bite.

123 f monoclonal antibodies (mAbs) , while alpha-gal attached to Fc glycans was not.

124 eriments, sera were pre-incubated with alpha-gal or protein G to deplete IgG Ab. alpha-Gal-specific I

125 the clinical outcome of patients with alpha-gal syndrome compared with subjects with asymptomatic al

126 significantly higher in patients with alpha-gal syndrome compared with those in sensitized subjects.

127 e recent finding is that patients with alpha-gal syndrome do not have detectable IgG4 to the oligosac

128 eters for distinguishing patients with alpha-gal syndrome from subjects with asymptomatic alpha-gal s

129 cts) was performed in 21 patients with alpha-gal syndrome, 12 alpha-gal-sensitized subjects, and 18 c

130 eas the prevalence of individuals with alpha-gal-sIgE levels >/=0.35 kUA /L was 19.3%.

131 found in 8.6% of the participants with alpha-gal-sIgE levels >/=0.35 kUA /L.

132 tivity to antivenom is associated with alpha-gal.

133 ly abolished after pre-incubation with alpha-gal.

134 were then performed between BM12 donors and gal-3 null recipients on a C57BL/6 background.

135 ns show distinct differences in the glc- and gal-PAS systems that correlate well with observed differ

136 s reliable representations of novel glc- and gal-PASs.

137 Anti-gal antibodies in patients with liver cirrhosis were red

138 risingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their abi

139 with increased levels of this modified anti-gal antibody had increased levels of markers of bacteria

140 The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrho

141 bacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased ba

142 exhibited by target gene expression and BAT-gal staining.

143 ither adenovirus Ang-1 (Ad-Ang-1) or Ad-beta-gal systemically immediately after ligation of the left

144 sity compared with pigs treated with Ad.beta-gal was found at 3 months and suggests an angiogenic rol

145 nt (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanced ca

146 g for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

147 4.2% (P=0.004) in pigs treated with Ad.beta-gal.

148 dium to large proteins (HRP, 44 kDa and beta-gal, 465 kDa) and antibodies (ca. 150 kDa).

149 rease of 3.1 and 2.7 units (for BSA and beta-gal, respectively) attributed to selective crystallizati

150 growth arrest and senescence-associated beta-gal (SA-beta-gal) activity.

151 kers such as p16, senescence-associated beta-gal, and gammaH2AX, in addition to more recent markers (

152 the inhibitory molecule daunorubicin by beta-gal.

153 hitectures to create agents that detect beta-gal activity by modulating the coordination of water to

154 th excellent performance for endogenous beta-gal detection offer a unique option for visualization an

155 ontrast, LECs do not present endogenous beta-gal in the context of MHC-II molecules to beta-gal-speci

156 g ability, Lyso-Gal realizes endogenous beta-gal visualization in lysosomes and shows brighter fluore

157 me activity in a mouse model expressing beta-gal.

158 xperiments showed that the newly formed beta-gal(+) SMC were not derived from circulating bone marrow

159 beta-galactosidase (beta-gal) and beta-glucuronidase (beta-glucur) are both produ

160 the procedure with beta-galactosidase (beta-gal) as the detection enzyme.

161 to release endemic beta-galactosidase (beta-gal) from the bound bacterial cells; (3) the release of

162 imals, staining for beta-galactosidase (beta-gal) identifies cells in which NF-kappaB has been activa

163 monstrate that when beta-galactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells

164 us (rAd.A20) or rAd.beta-galactosidase (beta-gal), implanted, harvested 4 weeks after transplantation

165 beta-Galactosidase (beta-gal), one of the typical lysosomal glycosidases, is repo

166 bumin (BSA) and ii) beta-galactosidase (beta-gal), was investigated by micro-flow imaging (MFI) durin

167 the omega-domain of beta-galactosidase (beta-gal).

168 e models expressing beta-galactosidase (beta-gal).

169 odies conjugated to beta-galactosidase (beta-gal).

170 operon encoding for beta-galactosidase (beta-gal).

171 reased expression of beta-galactosidase(beta-gal) plasmid in rat brain tissue in comparison to the si

172 sidosis patients with recombinant human beta-gal (rhbeta-gal) produced in Chinese hamster ovary cells

173 ace conditioning, we observed increased beta-gal staining in the nucleus accumbens (NAC) shell and do

174 The endogenous and phage-induced beta-gal was detected using the electrochemical method with 4

175 release of the endogenous intracellular beta-gal from E. coli following infection.

176 sidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells undergo deletion via the PD-1/P

177 rphic mice expressing a promoter-linked beta-gal reporter to show that inflammatory colitis suppresse

178 idase beta1 (GLB1) gene cause lysosomal beta-gal deficiency, resulting in accumulation of galactose-c

179 ing ability was developed for lysosomal beta-gal detection and imaging in ovarian cancer cells (SKOV-

180 erized by a large flat cell morphology, beta-gal staining and irreversible loss of regenerative (i.e.

181 beta-gal was sufficient for normalizing beta-gal activity and mediating substrate clearance for sever

182 bility to trigger the overexpression of beta-gal during the infection of E. coli.

183 ion of E. coli by (1) overexpression of beta-gal in E. coli during the specific infection and (2) rel

184 el of expression of the omega-domain of beta-gal in the model K12 strains allowed us to detect, on av

185 und bacterial cells; (3) the release of beta-gal was detected using chlorophenol red-beta-d-galactopy

186 nary PW1(+) cells and the proportion of beta-gal(+) vascular SMC were increased, indicating a recruit

187 accumulation of a prelysosomal pool of beta-gal, resulting in activation of the unfolded protein res

188 this complementation-an active form of beta-gal-was detected colorimetrically, and the high level of

189 s from yellow to red in the presence of beta-gal.

190 virus encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

191 with antibodies against GFP, DsRed, or beta-gal using the method of immunolabeling-enabled three-dim

192 together with a bifunctional 6-phospho-beta-gal/glucosidase, Gan1D.

193 ls in nontransduced, and rAd.A20 or rAd.beta-gal-transduced human SMC cultures after cytokine treatme

194 Ink4a), p21, senescence-associated (SA) beta-gal activity, and SA secretion of proinflammatory cytoki

195 With age, NSCs exhibited increased SA-beta-gal activity and decreased proliferation and pool size i

196 cence-associated beta-galactosidase (SA-beta-gal) activation, and increased mRNA expression of a subs

197 cence-associated beta-galactosidase (SA-beta-gal) activity but an increase in adenosine triphosphate

198 ecies (iROS), SA-beta-galactosidase (SA-beta-gal) activity, and autofluorescence (AF) was assessed by

199 and senescence-associated beta-gal (SA-beta-gal) activity.

200 cence-associated beta-galactosidase (SA-beta-gal), p16Ink4a, and p53 in lamin A/C-deficient muscles a

201 scence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression.

202 The beta-gal catalyzed PAPG to an electroactive species p-aminoph

203 Here, we show, using the beta-gal gene as a reporter, that amber, ochre, and opal supp

204 l in the context of MHC-II molecules to beta-gal-specific CD4 T cells.

205 Importantly, LECs transfer beta-gal to dendritic cells, which subsequently present it to

206 f primary ovarian cancer cells by using beta-gal as the biomarker.

207 (-/-)) created by replacing exon 2 with beta-gal and neo cassettes.

208 ctopyranoside (CPRG), which reacts with beta-gal to produce chlorophenol red (CPR) in a bacteria conc

209 escence at 725 nm after incubation with beta-gal.

210 h observed differences in solubility between gal-PASs and glc-PASs.

211 ning cost, for example, approximately 1 cent/gal for 95-RON E20 or 97-RON E30, and 3-5 cent/gal for 9

212 l for 95-RON E20 or 97-RON E30, and 3-5 cent/gal for 95-RON E10, 98-RON E20, or 100-RON E30.

213 heir flexibilities reported here for E. coli gal promoters may help construction of synthetic promote

214 hatase activity, while addition of exogenous gal-3 reduced phosphatase activity.

215 Porcine RMEC expressed gal-alpha(1,3)-gal, N-glycolylneuraminic acid, and Dolic

216 studies and immunohistochemical analysis for gal-3 and NIS expression.

217 The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane

218 stern blot and polymerase chain reaction for gal-3 and sodium-iodide symporter (NIS) expression.

219 Our results suggest a potential role for gal-3 in CAI, and this represents a potentially exciting

220 Marmosets maintained on 30% galactose (gal)-rich diet for 2 years were monitored for retinal va

221 scherichia coli lactose (lac) and galactose (gal) operons precludes access to key recognition element

222 Glucose- (glc-) and galactose- (gal-) PAS 10-mer structures are synthesized and investig

223 sine kinase receptor (sFlt)-1, and galectin (gal)-3.

224 gas zones per well (4.7-4.9 x 10(6) gallons [gal]/well).

225 When Tim-3(+) T cells encounter high gal-9 levels, they are deleted.

226 tion (galectin-3 immunohistochemistry (IHC); gal-3), and fibrosis (col1a1 IHC) was performed on termi

227 uced expression of interleukin-4 (P=0.02) in gal-3 null mice suggest possible mechanisms by which gal

228 verse fibrotic tissue, and mice deficient in gal-3 have reduced fibrosis in kidney, liver, and lung m

229 Furthermore, disease severity was greater in gal-1 knockout mice compared with their wild-type counte

230 ular atrophy (P<0.0001), and upregulation in gal-3 expression (P=0.002), compared with syngeneic cont

231 Transplanting BM12 kidneys into gal-3 null mice resulted in significant preservation of

232 carcinoma cells investigated were invariably gal-3-positive while presenting low or lost NIS expressi

233 tic systemic clearance of (1)(8)F-FDGal (K*(+gal) from linear analysis of data (Gjedde-Patlak method)

234 Mean K*(+gal) determined from the PET study was 0.019 L of blood/

235 MTS-gal is bound covalently, forming a disulfide bond with C

236 Anti-non gal antibodies are produced in xenograft recipients agai

237 ts indicated that the production of anti-non gal antibodies is much slower than that of the anti-Gal

238 ha-gal epitopes have suggested that anti-non gal antibodies mediate acute and chronic rejection of xe

239 Anti-non gal antibodies were found to be continuously produced as

240 not fully inhibit the production of anti-non gal antibodies.

241 Overcoming the anti-non gal antibody barrier will require immunosuppressive agen

242 ng leukocytes was unaltered by abrogation of gal-3, but reduced expression of YM1 (P=0.0001), a marke

243 Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; r

244 The many effects of gal-1 treatment include reduction in the production of p

245 ation of CD45 is important for regulation of gal-3-mediated signaling.

246 to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity.

247 howed incipient microaneurysms in retinas of gal-fed marmosets.

248 l tortuosity were observed in the retinas of gal-fed marmosets.

249 The role of gal-3 in CAI is examined in this study.

250 resent study investigated transplantation of gal-1-secreting neural stem cell (s-NSC) into ischemic b

251 way to reduce disease by increasing Tim-3 or gal-9 engagement.

252 neuroprotection than non-engineered NSCs or gal-1-overexpressing (but non-secreting) NSCs.

253 Treatment with recombinant gal-1 significantly diminished stromal keratitis lesion

254 i cAMP-CRP (cAMP receptor protein) regulated gal promoters by in vitro transcription assays.

255 significantly reduced biopsy-based relative gal-3 levels (P < 0.001), whereas INT-767 and liraglutid

256 c DNA-binding proteins; i.e., lac repressor, gal repressor, and lambda O protein, are able to divide

257 our in vitro biophysical findings for rhbeta-gal, which include pH-dependent and concentration-depend

258 ents with recombinant human beta-gal (rhbeta-gal) produced in Chinese hamster ovary cells enabled dir

259 tricularly (ICV) administered dose of rhbeta-gal (100 mug) resulted in broad bilateral biodistributio

260 Weekly ICV dosing of rhbeta-gal for 8 weeks substantially reduced brain levels of ga

261 in broad bilateral biodistribution of rhbeta-gal to critical regions of pathology in a mouse model of

262 A single, low dose (3 nm) of rhbeta-gal was sufficient for normalizing beta-gal activity and

263 vary cells enabled direct and precise rhbeta-gal delivery to acidified lysosomes.

264 We found that rhbeta-gal uptake by the fibroblasts is dose-dependent and satu

265 ed cell death, as demonstrated by the SAbeta-gal assay.

266 Using a combination of Salmon-gal and tetranitroblue tetrazolium, we were able to visu

267 Here, we show that Salmon-gal in combination with tetrazolium salts provides a mor

268 To accomplish this goal, secretory gal-1 was stably overexpressed in NE-4C neural stem cell

269 some of the GalR specific DNA binding sites (gal operators), we used the chromosome conformation capt

270 e gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the c

271 enescence-associated ss-galactosidase (SA-ss-gal), and p16(INK4a) were increased 2-, 8-, and 20-fold

272 data identify a novel role for cell-surface gal-3 and CD45 in DLBCL survival and suggest novel thera

273 activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activ

274 Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS

275 visualization of thyroid tumor by targeting gal-3 was demonstrated in the absence of radioiodine upt

276 dge, our findings are the first to show that gal-1 treatment represents a useful approach to control

277 nes [double knockout (DKO)] that produce the gal-alpha(1,3)-gal and N-glycolylneuraminic acid xenoant

278 (2) antigal-3 tracer showed high affinity to gal-3 (dissociation constant, ~3.9 nM) and retained immu

279 gal-9 pathway engagement was augmented using gal-9 transgenic recipients, GVHD lethality was slowed.

280 Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radio

281 ll mice suggest possible mechanisms by which gal-3 may promote renal transplant fibrosis.

282 While gal-3 can localize to intracellular sites, gal-3 is secr

283 X-gal analysis has shown strong beta-galactosidase activit

284 X-gal staining revealed that Wnt/beta-catenin signaling ac

285 ations of M1 ipRGCs, which was assessed by X-gal staining in R6/2-OPN4(Lacz/+) male mice, contributed

286 proximal promoter activity was analyzed by X-gal staining.

287 se in embryos at stages when the customary X-gal reaction failed to detect staining.

288 a gene-trap mouse model for PRCP deletion, X-gal staining was performed to further determine PRCP dis

289 Agrobacterium mannitol (ABM) agar medium, X-gal, and a biosensor.

290 ng in blue pigmentation in the presence of X-gal.

291 encoded by lacZ, is usually detected using X-gal in combination with ferric and ferrous ions.

292 distribution of PLAG1 in the testis using X-gal staining; (ii) transcriptomic consequences of PLAG1

293 ation on ABM agar medium supplemented with X-gal (ABMX-gal).

294 yme was localised in germinated seeds with X-gal activity staining and shown to be expressed prominen

295 oxide nanoparticles loaded gallic-acid (ZnO@gal) content were synthesized in order to evaluate the e

296 erial compatibility between chitosan and ZnO@gal matrices.

297 Ch-ZnO@gal films possess significant antibacterial potential an

298 oparticles loaded gallic-acid films, (Ch-ZnO@gal) have been prepared aiming for their exploitation as

299 lts have shown that the incorporation of ZnO@gal into chitosan films remarkably enhanced the desired

300 sized in order to evaluate the effect of ZnO@gal on their optimum mechanical and biological potential